Infectologia
Estudo de coorte | Desfechos relacionados a deglutição e voz em pacientes hospitalizados com COVID-19.
18 Jun, 2021 | 10:33hEstudo relacionado: Characterization of dysphagia and laryngeal findings in COVID-19 patients treated in the ICU—An observational clinical study – PLOS One
Estudo randomizado | Tofacitinibe reduziu o risco de morte ou insuficiência respiratória em pacientes hospitalizados com pneumonia por Covid-19.
17 Jun, 2021 | 11:06hTofacitinib in Patients Hospitalized with Covid-19 Pneumonia – New England Journal of Medicine
Comunicado de imprensa: Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia
Comentário no Twitter:
Patients who were hospitalized with #COVID19 pneumonia were randomly assigned, at a median of 10 days after symptom onset, to receive tofacitinib or placebo. At 28 days, the risk of death or respiratory failure was lower in the tofacitinib group. #IDTwitter
— NEJM (@NEJM) June 16, 2021
[Preprint] Estudo RECOVERY descobre que a combinação de anticorpo monoclonal Regeneron reduz as mortes de pacientes hospitalizados com COVID que não desenvolveram sua própria resposta imunológica.
17 Jun, 2021 | 11:04hComunicado de imprensa: RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response
Estudo original (preprint): Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv
Comentários: Monoclonal antibodies cut risk of dying from COVID-19—but only in some patients – Science E Antibody combo cuts COVID deaths by 20% in very ill seronegative patients – CIDRAP E Regeneron antibody saves lives in some hospitalized Covid patients, study finds – STAT E Expert reaction to press release from the RECOVERY trial reporting that Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response – Science Media Centre
Comentário no Twitter
RECOVERY Pre-print:
In patients hospitalised with COVID-19 but no natural antibody response, monoclonal antibody infusion:
– reduced mortality
– increased speed of discharge
– reduced progression to invasive mechanical ventilation or deathhttps://t.co/rpDk4eUhmm pic.twitter.com/wXegKcDZg8— Martin Landray (@MartinLandray) June 16, 2021
Agora, o CDC chama a variante Delta do coronavírus de “variante de preocupação”.
17 Jun, 2021 | 11:02hCDC now calls coronavirus Delta variant a ‘variant of concern’ – CNN
Diretriz: SARS-CoV-2 Variant Classifications and Definitions – Centers for Disease Control and Prevention
Comentário no Twitter
BREAKING—CDC now officially declares #DeltaVariant a “variant of concern”—because much more transmissible (50% faster than #B117, 2x than original strain), more severe (2.5x hospitalization risk than B117, 4x original) & 1 dose vaccine evasive.🧵 #COVID19https://t.co/jZCgfzFLla pic.twitter.com/SszvXuysze
— Eric Feigl-Ding (@DrEricDing) June 15, 2021
[Comunicado de imprensa – Ainda não publicado] CureVac falha como vacina contra COVID-19 em estudo, com 47% de eficácia.
17 Jun, 2021 | 11:01hCureVac Fails in Pivotal COVID-19 Vaccine Trial With 47% Efficacy – AP / Reuters
Ver também: CureVac’s COVID-19 shot just failed in a large trial, a major setback for the Gates-backed biotech – Insider
Comunicado de imprensa: CureVac provides update on phase 2b/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV
Comentário no Twitter (fio – clique para saber mais)
Bad new for CureVac's vaccine: it didn't make it over the efficacy bar in its 2nd interim analysis – only 47%. Not bad enough to be out for the count – it's 134 events (symptomatic Covid-19) & final is at 185 – but ….1/2 https://t.co/4GsLzgP7AT HT @noviceprize @megtirrell
— Hilda Bastian, PhD (@hildabast) June 16, 2021
Série de casos | 7 casos de miocardite após vacinação baseada em mRNA contra COVID-19.
17 Jun, 2021 | 11:00hMyocarditis after BNT162b2 and mRNA-1273 Vaccination – Circulation
Relacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Série de casos | Achados clínicos e de ressonância magnética em 4 casos de miocardite após vacinação baseada em mRNA contra COVID-19.
17 Jun, 2021 | 10:58hComentário: Possible Association Between COVID-19 Vaccine and Myocarditis – American College of Cardiology
Relacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Série de casos | Miocardite sintomática aguda em 7 adolescentes após vacinação baseada em mRNA contra COVID-19.
17 Jun, 2021 | 10:57hRelacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
De acordo com um novo relatório, quase 25% dos pacientes que tiveram COVID-19 desenvolvem sintomas de longa duração.
16 Jun, 2021 | 10:55hAlmost 25% of COVID-19 Patients Develop Long-Lasting Symptoms, According to a New Report – TIME
Relatório original: A Detailed Study of Patients with Long-Haul COVID – FAIR Health
Comentário no Twitter (fio – clique para saber mais)
📍1 in 4–almost a quarter of people infected develop at least one lingering health problem after 30 days with #COVID19. The most common included pain, breathing trouble, high cholesterol, malaise and/or fatigue and high blood pressure. 🧵 https://t.co/G4uPtnq86A
— Eric Feigl-Ding (@DrEricDing) June 15, 2021